

Special Issue

Urinary Tract Infections: New Insights into Diagnosis, Treatment and Pathogenesis

Message from the Guest Editor

Urinary tract infections are one of the most common infections in humans. They affect 50% of women and 12% of men and children worldwide. Women are more prone to have a UTI, and it is reported that, at the age of 32, 50% would have at least 1 episode of infection, with 20-30% having another episode in the next 6 months. One of the biggest challenges in treating a UTI is increasing antimicrobial resistance. UTIs are commonly managed with antibiotics and, along with respiratory infections, is the most common reason for antibiotic prescription in primary care. Long-term and uncontrolled use of antibiotics has led to the emergence of multidrug-resistant microorganisms. Antibiotic choice is generally empirical and the primary treatment option. Therefore, there is an urgent need for better antibiotic therapies, the development of new antibiotics or non-antibiotic alternatives, and clinical trials. In this Special Issue, we seek manuscript submissions that develop our knowledge in all aspects of urinary tract infections, from diagnosis to treatment and pathogenesis. We encourage the submission of manuscripts concerning the use of antibiotics or novel therapies.

Guest Editor

Dr. Paola Scavone

Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay

Deadline for manuscript submissions

closed (30 September 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/169347

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)